EDEN PRAIRIE, Minn.,
Jan. 23, 2018 /PRNewswire/
-- MIVI Neuroscience, a company dedicated to developing
best-in-class treatment solutions to improve clinical outcomes for
stroke patients, today announced that Bob
Colloton has joined the company's senior management team as
Chief Commercial Officer.
Bob brings 27 years of proven experience in medical device sales
and market development and branding expertise, with a deep
understanding of the neurovascular market in particular. Most
recently he was vice president of Marketing and Sales (USA) for Neuravi Limited and prepared the
company for its US market launch of the EmboTrap Revascularization
Device. Prior to Neuravi, Bob was vice president Global Sales
and Marketing at Revision Optics. He also served as vice
president of Global Sales and Marketing at Micrus Endovascular,
where he built the sales team and grew the business to become a
leading player in neurovascular aneurysm therapy. He also held
senior leadership positions in sales and marketing at VNUS Medical,
TransVascular, Inc., and Cardiometrics.
"We are excited to bring our unique and broad stroke therapy
system, featuring both the R4Q and the DAISe technology, to
physicians around the world. At MIVI we are engineering the company
for the future, and Bob is a key element of this development. Bob's
addition will build on the current organization strengths,
demonstrating our investment in building the leadership team for
the future," said Jim McCollum,
Interim CEO at MIVI. "Bob truly understands this market and the
needs of the neurointerventionalists, and he shares our passion for
delivering value and striving for excellence. We are thrilled to
welcome him to the MIVI family."
"I'm very excited to join MIVI and continue to help improve
treatments and thus patient outcomes in the neurovascular market,
especially at this exciting time of tremendous growth in acute
ischemic stroke treatment," said Bob. "MIVI is a dynamic and
innovative company, and I'm inspired by the dedication of the
entire team - especially Matt Ogle
(our Founder and CTO), Joe Glab (our
VP of Sales), Randy LaBounty (our VP
of Clinical and Regulatory Affairs) and Scott Olson (our VP of Operations). I look
forward to working with the worldwide neurointerventional community
to help advance stroke treatment for all patients."
MIVI Neuroscience, Inc. is focused on developing and
commercializing superior clinical solutions for
neurointerventional procedures. Adoption of endovascular
stroke therapy procedures is growing significantly worldwide since
compelling data from multiple large-scale randomized trials in 2016
and 2017 confirmed the value to rapidly clear occlusive clot
from large cerebral vessels. MIVI's innovative product
portfolio provides physicians with unique
devices that improve patient outcomes in these procedures
by reducing complications, shortening procedure times and
expanding treatment to more patients. More information about
MIVI can be found on our website, www.mivineuro.com.
View original
content:http://www.prnewswire.com/news-releases/mivi-neuroscience-selects-bob-colloton-to-lead-worldwide-commercialization-of-innovative-treatment-solution-for-ischemic-stroke-300586275.html
SOURCE MIVI Neuroscience